S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged

Sangamo Therapeutics (SGMO) Stock Forecast & Price Target

$0.51
+0.03 (+5.44%)
(As of 04/19/2024 08:51 PM ET)

Sangamo Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 7 Analyst Ratings

Analysts' Consensus Price Target

$4.93
862.85% Upside
High Forecast$10.00
Average Forecast$4.93
Low Forecast$1.00
TypeCurrent Forecast
4/23/23 to 4/22/24
1 Month Ago
3/24/23 to 3/23/24
3 Months Ago
1/23/23 to 1/23/24
1 Year Ago
4/23/22 to 4/23/23
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$4.93$4.93$4.68$12.80
Predicted Upside862.85% Upside380.69% Upside412.87% Upside327.81% Upside
Get Sangamo Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter.

SGMO Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SGMO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Sangamo Therapeutics Stock vs. The Competition

TypeSangamo TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.29
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside862.85% Upside947.54% Upside11.94% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/19/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$3.00 ➝ $5.00+487.54%
3/14/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingSector Perform ➝ Sector Perform$2.00+145.10%
11/7/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Hold
11/6/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Equal Weight$1.00+110.52%
8/11/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Argyrides
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$16.00 ➝ $10.00+825.92%
8/9/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$11.00 ➝ $9.00+689.47%
4/28/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$4.20 ➝ $3.90+178.57%
4/28/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$5.00 ➝ $1.50-6.25%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:13 AM ET.

SGMO Price Target - Frequently Asked Questions

What is Sangamo Therapeutics's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Sangamo Therapeutics stock is Hold based on the current 1 sell rating, 3 hold ratings and 3 buy ratings for SGMO. The average twelve-month price prediction for Sangamo Therapeutics is $4.93 with a high price target of $10.00 and a low price target of $1.00. Learn more on SGMO's analyst rating history.

Do Wall Street analysts like Sangamo Therapeutics more than its competitors?

Analysts like Sangamo Therapeutics less than other Medical companies. The consensus rating for Sangamo Therapeutics is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how SGMO compares to other companies.

Does Sangamo Therapeutics's stock price have much upside?

According to analysts, Sangamo Therapeutics's stock has a predicted upside of 380.69% based on their 12-month stock forecasts.

What analysts cover Sangamo Therapeutics?

Sangamo Therapeutics has been rated by HC Wainwright, and Royal Bank of Canada in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:SGMO) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners